Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

MLA

Daniel V.T. Catenacci, et al. “Biomarker-Guided Enrichment of the Antitumor Activity of Margetuximab (M) plus Pembrolizumab (P) in Patients with Advanced HER2+ Gastric Adenocarcinoma (GEA).” Annals of Oncology, vol. 29, Oct. 2018, p. viii223. EBSCOhost, https://doi.org/10.1093/annonc/mdy282.046.

APA

Daniel V.T. Catenacci, Jon M. Wigginton, Philip J. Gold, T. Wu, Hope E. Uronis, Keun Wook Lee, Haeseong Park, J. Yen, A. Wynter-Horton, Y.-J. Bang, Aleksandra Franovic, John Muth, Peter C. Enzinger, Jill Lacy, Justin I. Odegaard, Y-K. Kang, M.C.H. Ng, Sung-Ji Park, Jan Baughman, & Jan K Davidson-Moncada. (2018). Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). Annals of Oncology, 29, viii223. https://doi.org/10.1093/annonc/mdy282.046

Chicago

Daniel V.T. Catenacci, Jon M. Wigginton, Philip J. Gold, T. Wu, Hope E. Uronis, Keun Wook Lee, Haeseong Park, et al. 2018. “Biomarker-Guided Enrichment of the Antitumor Activity of Margetuximab (M) plus Pembrolizumab (P) in Patients with Advanced HER2+ Gastric Adenocarcinoma (GEA).” Annals of Oncology 29 (October): viii223. doi:10.1093/annonc/mdy282.046.